RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
Kazuhiko NakagawaEdward B GaronLing GaoSophie CalliesAnnamaria ZimmermannRichard WalgrenCarla Visseren-GrulMartin ReckPublished in: Cancer chemotherapy and pharmacology (2022)
ClinicalTrials.gov, NCT02411448.